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ABSTRACT 16 
WU and KI polyomaviruses (WUPyV, KIPyV) have been detected in respiratory, blood, stool 17 
and lymphoid tissue, but not in urine samples. PCR based detection revealed higher frequency 18 
in immunocompromised individuals. In this study the prevalence of WUPyV and KIPyV was 19 
analyzed in respiratory, urine and blood samples from renal transplant patients compared with 20 
healthy individuals. WUPyV and KIPyV were detected by nested PCR. The PCR products 21 
were sequenced and viral DNA loads were determined by quantitative real-time PCR. 22 
WUPyV and KIPyV were found  in plasma (3.6 %; 7/195), urine (14 %; 7/50) and respiratory 23 
samples (10 %; 9/90) of renal transplant patients, but not in plasma (0/200) and urine (0/36) 24 
specimens from healthy blood donors. WUPyV and KIPyV were detected mainly early after 25 
renal transplantation and the viral loads were low. A higher prevalence of WUPyV was found 26 
in plasma and urine samples, KIPyV was found more frequently in respiratory samples from 27 
renal transplant patients. It is hypothesized that immunosuppression due to the transplantation 28 
may result in reactivation of these viruses or may establish greater susceptibility to infection 29 
with  KIPyV and WUPyV. 30 
31 
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INTRODUCTION 32 
Serological studies suggest that KI and WU polyomaviruses (KIPyV, WUPyV) are 33 
widespread. It is thought that primary infection may occur in childhood because the 34 
seropositivity for both viruses is high in children and reaches 70-80 % in adults [Neske et al., 35 
2010; Nguyen et al., 2009]. Both WUPyV and KIPyV have been identified from respiratory 36 
specimens of patients with respiratory symptoms [Allander et al., 2007; Gaynor et al., 2007]. 37 
Although the pathogenic roles of these viruses have not been clarified, PCR based detection 38 
revealed 0.4-9 % prevalence in respiratory specimens of immunocompetent patients and 39 
higher frequency in children and immunocompromised individuals [Bialasiewicz et al., 2009; 40 
Dalianis et al., 2009; Mourez et al., 2009]. Viral DNA was also detected in blood samples 41 
from immunocompromised patients and children [Miller et al., 2009; Neske et al., 2009], in 42 
stool samples of children with gastroenteritis [Bialasiewicz et al., 2009; Neske et al., 2009], in 43 
lymphoid tissues from immunocompromised patients [Sharp et al., 2009], but not in urine 44 
samples from immunocompromised and immunocompetent patients [Bialasiewicz et al., 45 
2009; Bofill-Mas et al., 2010; Gaynor et al., 2007]. The higher prevalence in 46 
immunocompromised patients suggest that these viruses may cause more severe problems in 47 
these individuals in a manner similar to the effect of BK and JC virus (BKV, JCV) [Jiang et 48 
al., 2009].  49 
 The prevalence of WUPyV and KIPyV has been studied and examined in respiratory, urine 50 
and blood samples from renal transplant patients. 51 
52 
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MATERIALS AND METHODS 53 
Test specimens. 195 blood samples from 195 patients (82 women, 113 men; median age 45.7 54 
years; range 7-68.8 years ) were collected at different times after renal transplantation 55 
(median 1188 days, range 3-7108). For control measurements, 200 blood samples from 200 56 
healthy blood donors were taken (75 men, 125 women, median age 39 years, range 10-74 57 
years). Fifty urine samples from 50 transplant patients were also collected after 58 
transplantation (range 5-6230 days; median 141 days). Thirty six urine specimens from 59 
healthy blood donors were used as controls. Ninety upper respiratory tract specimens  using 60 
throat swabs from 90 renal transplant individuals were obtained 18-6230 days after the 61 
transplantation (median 1177 days). 62 
Nucleic acids from 200 µL plasma, centrifuged for 10 min at 180×g at 4 ºC, 200 µl urine 63 
specimen and throat swab sample washed in 200 μL buffer were isolated using High Pure 64 
Viral Nucleic Acid Kit (Roche, Basel, Switzerland) according to the manufacturer’s 65 
instructions. Nucleic acid was eluted in 50 µl and stored at -20 ºC until use.  66 
The Regional and Institutional Ethics Committee of University of Debrecen approved all of 67 
the studies. All patients gave their written informed consent.  68 
Qualitative and quantitative detection of KIPyV and WUPyV DNA. To detect WUPyV and 69 
KIPyV DNA, the first round of WUKI nested-PCR was carried out with WUKI_OS and 70 
WUKI_OAS primers as described previously [Sharp et al., 2009] in a final volume of 20 µL 71 
containing 5 µL DNA solution, GenAmp Fast PCR Master Mix (Applied Bisystems, Foster 72 
City, CA, USA) and 10-10 pmol of each primer. For the second round, 4 µL of the PCR 73 
product from the first round was amplified in 20 μL final volume using GenAmp Fast PCR 74 
Master Mix and 10-10 pmol WUKI_IS and WUKI_IAS primers [Sharp et al., 2009]. The 75 
annealing temperature was 60 ºC in both rounds. Plasmids containing the genome of WUPyV 76 
and KIPyV were used as positive controls [Gaynor et al., 2007; Lindau et al., 2009]. The 77 
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sensitivity of this nested-PCR was <100 genome equivalent/mL (GEq/mL). Since this PCR 78 
method amplifies both WUPyV and KIPyV DNA and does not differentiate between them, 79 
the PCR products were sequenced by using the ABI PRISM 3100 Genetic Analyzer (Applied 80 
Biosystems). At the same time, real-time PCR for WUPyV and also for KIPyV was 81 
performed with primers and probes described previously [Lindau et al., 2009] with 5 μL DNA 82 
to confirm the result of the nested-PCR and to quantify the viral loads in the samples.  83 
χ2 and Fisher’s exact test was used to assess the difference in frequency for categorical 84 
variables. Mann-Whitney U test was applied for continuous variables. A difference was 85 
considered significant if p value was less then 0.05.  86 
87 
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RESULTS  88 
PCR prevalence of WUPyV and KIPyV in plasma samples. Seven (3.6 %) of 195 plasma 89 
samples from transplant patients and none from 200 healthy blood donors were positive by 90 
WUKI PCR (p<0.01; Table 1.). Sequencing of the PCR products revealed that two samples 91 
were positive for KIPyV and five for WUPyV DNA. The level of DNA load in six plasma 92 
samples was less then 250 GEq/mL urine, below the limit of detection, and 2.5 X 10
2
 KIPyV 93 
GEq/mL in one specimen. Significant difference was found between polyoma-positive and 94 
negative samples regarding the time after renal transplantation (p=0.001) (Table 2.). 95 
PCR prevalence of WUPyV and KIPyV in urine samples. Seven (14 %) urine specimens 96 
from transplanted patients and none from 36 healthy blood donors were positive for WUKI by 97 
PCR (p<0.05; Table 1.). One sample was KIPyV DNA positive (viral load was < 250 98 
GEq/mL plasma) and six samples were WUPyV DNA positive by sequencing. The viral loads 99 
of four samples were < 250 GEq/mL, and two samples had 5 X 10
2 
and 1.1 X 10 
3
 GEq / mL 100 
plasma. PCR positive samples were collected significantly earlier after transplantation then 101 
the negative samples (p=0.001) (Table 2.). In the case of two patients whose urine samples 102 
were WUPyV DNA positive (28.6 %), WUPyV viremia was also detected.  103 
Prevalence of WUPyV and KIPyV by PCR in respiratory samples. Nine (10 %) of 90 104 
respiratory samples were WUKI PCR positive (Table 1.). Six samples were KIPyV DNA 105 
positive (66.7 %) with viral loads ranging from 2.8 X10
2
 to 3.7 X 10
5
 GEq/mL (median 4.2 X 106 
10
4
; in two samples the viral load was below the limit of detection). Only one out of the three 107 
WUPyV positive samples had detectable viral load of 6.3 X 10
2
 GEq/mL. Statistical analysis 108 
revealed that the PCR positive samples were collected significantly earlier after 109 
transplantation then the PCR negative samples (p=0.002; Table 2.). The plasma sample of one 110 
patient with a KIPyV positive respiratory specimen was positive for WUPyV DNA, the 111 
plasma samples of the others were PCR negative. All of the patients with a positive 112 
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respiratory specimen had acute upper respiratory tract infection, but none of these samples 113 
were tested for any respiratory virus; a significantly higher frequency compared with the PCR 114 
negative patients (9/9 vs. 47/81; p=0.01).  115 
116 
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DISCUSSION 117 
This study revealed that WUPyV and KIPyV can be detected in blood, urine and respiratory 118 
samples from renal transplant patients, but these viruses were not found in blood and urine 119 
specimens from healthy blood donors.   120 
Viremia was detected in 3.6 % of the renal transplant patients, mostly early after 121 
transplantation, but not in healthy blood donors. Other studies have found only WUPyV in 122 
blood samples [Bialasiewicz et al., 2009; Miller et al., 2009; Neske et al., 2009], but apart 123 
from WUPyV (2.6 %), KIPyV (1 %) was detected in the current study in renal transplant 124 
patients. The viral loads were very low, ≤ 250 GEq /mL plasma. Previously, WU and KI 125 
polyomaviruses were not found in urine samples from immunocompromised, renal transplant 126 
patients, immunocompetent patients and pregnant women [Bialasiewicz et al., 2009; Bofill-127 
Mas et al., 2010; Gaynor et al., 2007]. In this study these viruses were not detected in urine 128 
specimens from healthy blood donors, but 14 % of the samples from renal transplant patients 129 
were positive for viral DNA. A higher prevalence of WUPyV was observed compared with 130 
KIPyV (6/7 vs. 1/7). The viruses appeared early after renal transplantation, and all of the 131 
positive samples were collected within two months after the transplantation. The viral loads in 132 
these urine samples were low (≤1.1 X 103 GEq/mL), but in two patients WUPyV viremia was 133 
also found at the same time. A different DNA isolation method in which samples were not 134 
stored and DNA was isolated immediately after the collection of the urine samples, primers 135 
and PCR conditions may be the reasons why these viruses were found while other investigator 136 
did not detect these viruses in urine samples [Bialasiewicz et al., 2009; Bofill-Mas et al., 137 
2010; Gaynor et al., 2007]. 138 
In immunocompetent individuals a slightly higher prevalence of WUPyV DNA was observed 139 
in the respiratory samples [Dalianis et al., 2009] and also the seroprevalence of WUPyV was 140 
found to be greater [Neske et al., 2010; Nguyen et al., 2009] compared with  KIPyV. In the 141 
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throat swab samples from renal transplant patients a higher prevalence of KIPyV (6/9; 6.7 %) 142 
then WUPyV (3/9; 3.3 %) was observed. This is in accordance with the results of Murez et al. 143 
[2009] who found a higher frequency of KIPyV in respiratory samples from 144 
immunocompromised patients. A significant difference was found between the PCR positive 145 
and the negative group of the patients regarding the date of samples collection. Viral DNA 146 
was detected mostly early after renal transplantation.  147 
The results of previous studies suggest that primary infection with WU and KI viruses occurs 148 
during childhood with subclinical or mild illness [Abedi Kiasari et al., 2008; Bialasiewicz et 149 
al., 2007; Gaynor et al., 2007; Neske et al., 2010]. Transmission can be fecal-oral and/or via 150 
the respiratory route [Dalianis et al., 2009]. Presumably, in a manner similar to BKV and 151 
JCV,  it may establish lifelong persistence [Jiang et al., 2009]. This study revealed that viruria 152 
with WUPyV and KIPyV can occur, so urine can also be a source of infection. The higher 153 
prevalence of WUPyV and KIPyV in respiratory samples from immunocompromised 154 
patients, and the findings that these viruses are present in blood and urine specimens from 155 
renal transplant patients, but not in healthy blood donors, suggest that similar to BKV and  156 
JCV, WUPyV and KIPyV might cause significant disease primarily in immunocompromised  157 
individuals. At the same time, because of the high rates of coinfections with other respiratory 158 
viruses, the pathological role and the clinical consequences of the KI and WU respiratory tract 159 
infections are not clean. Based on the knowledge of other human pathogen polyomaviruses it 160 
is hypothesized that immunosuppression due to transplantation may result in reactivation of 161 
these viruses, or may establish greater susceptibility to KIPyV and WUPyV [Jiang et al., 162 
2009]. Although viremia and viruria were found in the current study in renal transplant 163 
patients, the viral loads were low. In the case of BKV the level of viruria correlates with the 164 
degree of immunosuppression, and the higher viral loads in urine and blood samples can 165 
result in more severe clinical consequences [Ahsan and Shah, 2006]. Further follow up 166 
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studies of renal transplant patients may help to clarify whether the presence of WUPyV and 167 
KIPyV in urine and blood samples can result in severe disease as observed with BKV. 168 
169 
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 225 
Tables 226 
Table 1. Prevalence of WU and KI polyomaviruses in different samples from renal transplant 227 
patients and healthy blood donors 228 
 229 
  KI and WU polyomavirus  
DNA in samples, number (%) 
  
Sample 
source 
Sample 
KIPyV 
positive 
WUPyV 
positive 
Negative 
Total number 
of samples 
(patients) 
Renal 
transplant 
patients 
plasma 2 (1) 5 (2.6) 188 (96.4) 195 (195) 
Renal 
transplant 
patients 
urine 1 (2) 6 (12) 43 (86) 50 (50) 
Renal 
transplant 
patients 
throat swab 6 (6.6) 3 (3.3) 81 (90) 90 (90) 
Healthy blood 
donors 
plasma 0 (0) 0 (0) 200 (100) 200 (200) 
Healthy blood 
donors 
urine 0 (0) 0 (0) 36 (100) 36 (36) 
 230 
231 
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 232 
Table 2. Detection of WU and KI polyomaviruses after renal transplantation 233 
 234 
 
Days after renal transplantation, range 
(median) 
Samples from renal 
transplant patients 
WUPyV and  KIPyV 
positive 
Negative 
plasma 8-2122 (24) * 3-7108 (1271) 
urine 8-58 (30) * 7-6230 (745) 
throat swab 21-822 (101) 
#
 18-6230 (1177)  
*  p=0.001 vs. negative 
#
 p=0.002 vs. negative 
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